Physician profile
Huma Sohail
NPI 1053527275
$13,549.11
in general payments reported to CMS, 2019-2025
32 companies · $2,417 in 2025
The $2,417 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,574 · 2020: $293 · 2021: $1,603 · 2022: $2,414 · 2023: $2,456 · 2024: $2,791 · 2025: $2,417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,606 · Education: $57.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,606.31 |
| Education | $57.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,249.81 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Novartis Pharmaceuticals Corporation | $1,637.13 | 2019-2025 | |
| Amgen INC. | $1,157.83 | 2019-2025 | Enbrel, Otezla, Otezla |
| Ucb, INC. | $1,072.88 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $860.72 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $830.05 | 2019-2025 | Orencia |
| Janssen Biotech, INC. | $813.32 | 2019-2025 | Tremfya |
| Genzyme Corporation | $471.17 | 2019-2025 | |
| Glaxosmithkline, LLC. | $358.39 | 2019-2024 | Benlysta |
| Horizon Therapeutics Plc | $286.74 | 2019-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.62 | 2019-2025 | Ofev |
| Lilly USA, LLC | $207.00 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $201.72 | 2021-2025 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $190.97 | 2021-2024 | Saphnelo |
| Organon LLC | $159.63 | 2021-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $115.19 | 2019-2025 | Tymlos |
| Genentech USA, INC. | $106.61 | 2020-2025 | Actemra, Gazyva |
| Alexion Pharmaceuticals, INC. | $81.45 | 2019-2025 | Strensiq |
| Sobi, INC | $72.18 | 2022-2024 | |
| Actelion Pharmaceuticals US, INC. | $66.61 | 2021-2024 | Opsumit, Uptravi |
| Sanofi-Aventis U.S. LLC | $52.99 | 2019 | |
| Celgene Corporation | $50.29 | 2019 | |
| Merck Sharp & Dohme LLC | $50.01 | 2020-2025 | Capvaxive |
| Regeneron Healthcare Solutions, INC. | $34.95 | 2024 | Eylea |
| Ani Pharmaceuticals, INC. | $31.16 | 2025 | Purified Cortrophin Gel |
| Boston Scientific Corporation | $31.14 | 2025 | General - Pain Management |
| Mallinckrodt Enterprises LLC | $22.63 | 2019 | |
| Octapharma USA, INC. | $20.36 | 2025 | Octagam Immune Globulin (Human) |
| Sandoz INC. | $18.09 | 2024 | Hyrimoz |
| Invivyd INC | $17.16 | 2025 | Pemgarda |
| Gilead Sciences, INC. | $16.23 | 2019 | |
| Medexus Pharma, INC. | $13.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huma Sohail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.